Which psychedelic therapy is the most cost-effective? How can we determine the value of a psychedelic treatment? In this episode of The Integration Session, we discuss the crucial economic landscape of psychedelic therapies with Dr. Elliot Marseille, a health economist and founding director of the Collaborative for the Economics of Psychedelics at UC Berkeley and UC San Francisco. As a leading expert and author of several recent scientific publications on the topic, we explore the economic viability of psilocybin for treatment-resistant depression, the economic potential of group therapy models for conflict zones and low-income countries, and the crucial study design approaches to enhance affordability, feasibility, and regulatory impact.